

a troublesome problem
in modern gynaecology

***Candida* vaginitis during menstruation**

menstruation creates favourable conditions
for *Candida albicans*

The modern approach:

TRADEMARK
Nizoral

ketoconazole

**just 2 oral tablets daily
with a meal
for 5 days.**

Prescribing information

Presentation: white, flat, half scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each tablet contains 200 mg ketoconazole.

Uses: Nizoral is an orally active antimycotic for the treatment in adults of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I.-tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed.

Side-effects, precautions, contra-indications: contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂-blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and dizziness may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels, on the other hand, do not necessitate discontinuation of the treatment. Ketoconazole, when given together with cyclosporin A results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. Ketoconazole 200 mg once daily produces a transient decrease in plasma levels of testosterone. During long term therapy at this dose, testosterone levels are usually not significantly different from controls. In rare instances, gynaecomastia has been reported.



The British Council International Medical Courses

THE LIVER: A CLINICAL AND SCIENTIFIC UPDATE

20 January – 1 February 1985 Bristol/London

The aim of the course is to review the anatomy, physiology and biochemistry of the liver, the changes which take place in liver disease, diagnostic methods and the management of disorders of the liver. The Directors of Studies will be **Professor A E Read** of the Department of Medicine, University of Bristol and **Professor N McIntyre** of the Royal Free Hospital School of Medicine, University of London. The course is designed for experienced physicians wishing to be updated in this field.

Fee £695 (Residential only)

BLOOD TRANSFUSION

21 April – 3 May 1985 in Edinburgh

The aim of the course is to review the practice of blood transfusion in the 1980s and beyond against a background of the voluntary blood donor, a national blood transfusion service, the evolution of community self-sufficiency in blood, blood products and laboratory reagents and the clinical use of blood products. The Director of Studies will be **Dr J D Cash**, National Medical Director of the Scottish National Blood Transfusion Service. The course is designed for medically qualified doctors and graduate scientists with blood transfusion experience.

Fee £695 (Residential), £450 (Non-residential)

NEONATAL SURGERY

30 June – 12 July 1985 in Liverpool

This course is designed to provide an up-to-date review of current practice in neonatal surgery. The aetiology, pathology, diagnosis and treatment of individual conditions demanding urgent surgery in the first few days of life will be considered in detail. The course will be under the direction of **Professor James Lister** of the Department of Paediatric Surgery, University of Liverpool. The course is intended for experienced surgeons at or near consultant level with a major interest in paediatric surgery.

Fee £745 (Residential), £485 (Non-residential)

CANCER IN CHILDREN

2-8 June 1985 in London

Rather than provide coverage of all aspects of paediatric oncology, this course will focus on relevant recent laboratory research and on controversial areas in clinical practice. A number of tumours will, however, be discussed in depth. The Directors of Studies will be **Professor T J McElwain** of the Department of Medicine, Institute of Cancer Research, University of London and **Dr J Pritchard**, Senior Lecturer in Paediatric Oncology, Institute of Child Health, University of London. The course is intended for paediatric oncologists, paediatricians and medical oncologists with several years' experience of the clinical management of cancer in children.

Fee £460 (Residential), £295 (Non-residential)

GROWTH AREAS IN ONCOLOGY

9-15 June 1985 in London

The intention of this course is to focus on the major areas of basic research and clinical techniques expected to improve the management of various tumours. The Directors of Studies will be **Professor K D Bagshaw**, **Dr R H J Begent** and **Dr E S Newlands**, all of the Department of Medical Oncology, Charing Cross Hospital Medical School, University of London. The course is intended for medical oncologists, radiotherapists, haematologists, surgeons and senior clinicians with a major interest in oncology.

Fee £460 (Residential), £295 (Non-residential)

HUMAN TOXICOLOGY: PRESENT PROBLEMS AND FUTURE APPROACHES

12-24 May 1985 in Brighton

This course is designed for those involved in the assessment of the safe use of chemicals. It will be of particular interest to those physicians and scientists working in occupational medicine and responsible for the identification of real hazards from the use of chemicals. The Course Director will be **Professor J W Bridges**, Director of the Robens Institute of Industrial and Environmental Health and Safety at the University of Surrey. The course is designed for those involved in the assessment of the safe use of chemicals.

Fee £595 (Residential), £385 (Non-residential)

PAEDIATRIC NURSING

7-19 July 1985 in London

The purpose of this course, which is based at the Charles West School of Nursing, Hospitals for Sick Children, Great Ormond Street, London is to provide an up-to-date review of special areas of paediatric nursing and of the changing pattern of care. The course will be under the direction of **Miss B M Barchard**, Chief Nursing Officer and **Miss S Barlow**, Director of Nurse Education. The course is open to senior nurses involved in the clinical, managerial and teaching aspects of paediatric nursing.

Fee £615 (Residential), £395 (Non-residential)

FURTHER INFORMATION AND APPLICATION FORMS CAN BE OBTAINED FROM YOUR LOCAL OVERSEAS REPRESENTATIVE OF THE BRITISH COUNCIL OR FROM COURSES DEPARTMENT, THE BRITISH COUNCIL, 65 DAVIES STREET, LONDON W1Y 2AA.

ABC OF COMPUTING


Although computers are being widely used in medicine, their possibilities and limitations are still not clear to many potential users. This book, aimed at the non-expert, describes some of the uses of computers in medicine; because most doctors' involvement will be indirect, liaising with computer experts rather than designing systems themselves, the book concentrates on concepts rather than detailed descriptions of how computers work. It provides a useful introduction for the doctor who wants to know how computers can contribute to his practice of medicine.

Price: Inland £5.75;
Overseas £8.00*; USA \$14.00*
(Inland £5.25;
Overseas £7.50*; USA \$13.00*
to BMA members)

**including air mail postage*

Payment must be enclosed with order

Order your copy now
From: The Publisher
British Medical Journal
BMA House
Tavistock Square
London WC1H 9JR
or any leading bookseller



Tea and sympathy?



Diarrhoea is often a self-limiting affair.
But by the time patients consult their doctor, they have tried
the usual home remedies and want more than tea and sympathy...

Then it's time for a firm approach
with an antidiarrhoeal of universal repute.

All over the world doctors know:

WHEN IT COMES
TO DIARRHOEA
NOTHING WORKS
LIKE **Imodium** TRADEMARK


2 caps stat.
1 after each loose stool

JANSSEN
PHARMACEUTICA

the drug discovery company

IN HYPERTENSION AND ANGINA

puts it all together...



...in one tablet daily

TENORMIN

fits the profile of the ideal beta blocker
in hypertension and angina

'Tenormin' Prescribing notes:

Presentation: 'Tenormin' tablets containing atenolol 100mg are round, bi-convex, orange and film coated. **Uses:** Management of hypertension and angina pectoris. **Dosage:** Hypertension: One tablet daily. Angina: 100mg daily in single or divided doses. **Contraindications:** Heart block. Co-administration with verapamil. **Precautions:** Untreated cardiac failure, bradycardia, renal failure, anaesthesia and pregnancy. Clonidine withdrawal. **Side Effects:** Coldness of extremities and muscular fatigue. Sleep disturbance rarely seen. Rashes and dry eyes have been reported with beta blockers—consider discontinuance if they occur. Cessation of therapy with beta blockers should be gradual. **Pack size and Basic NHS cost:** 'Tenormin' 28's £6.98 **Product Licence Number:** 'Tenormin' 0029/0122.

Full prescribing information is available on request to the Company



Stuart Pharmaceuticals Ltd
Carr House, Carrs Road
Cheadle, Cheshire SK8 2EG

'Tenormin' is a trademark

